Within Basel neighbourhood and at the very heart of Europe (the triple border of France, Germany and Switzerland), Firalis is a pioneering biotechnology company, active in discovery, development and qualification of biomarkers (BM).
1) BIOMARKER PRODUCTS
Firalis develops BM-based diagnostic, prognostic and theranostic tools:
● RUO Kits (Research-Use-Only), based on validated innovative biomarkers
● IVD Tools (In Vitro Diagnostic), based on a combination of clinically qualified biomarkers
2) BIOMARKER R&D
● Development of proprietary BMs
- Cardiovascular, Inflammatory, Autoimmune and Neurology
● Drug Safety & Drug Efficacy
● Patient Stratification
● Personalized Medicine
3) BIOMARKER-RELATED CRO SERVICES
BM Discovery for laboratories, biotechs and pharmaceutical industry:
- Proteomics: Soluble biomarker measurements with several immunoassays technologies (ELISA, multiplex and high sensitivity platforms such as Luminex® BioPlex 200™, Meso Scale Discovery®, Singulex Erenna®, Protein Simple Ella™, Olink and Siemens Dimension® EXL™ 200)
- Genomics/Transcriptomics: Targeted sequencing of miRNA and mRNA (HTG EdgeSeq), lncRNA screening via Firalis proprietary platform, Next-Generation Sequencing (NGS) services (RNA-Seq, whole genome and exome sequencing, etc.) and qPCR/microfluidic qPCR (Gene Expression, SNP, CNV, etc.)
- Flow Cytometry: Immunophenotyping of preclinical and clinical samples, monitoring of pharmacodynamics on target cells in response to treatment and biomarker discovery
- Assay development and validation on various platforms, development of critical reagents (antibodies and proteins)
- Biobanking and sample repository services supported by LIMS
- Data analysis using multi-parametric statistics and development of predictive models
- Support of regulatory activities related to biomarker qualification with Health Authorities (FDA/EMA)
- Quality environment (ISO 9001, ISO 13485 (GMP), ISO 17025 (GLP/GCLP))
For more information please visit our website.
Company Details
- Employees
- 30
- Founded
- -
- Address
- 35, Rue Du Fort, Huningue,68330,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- firalis.com
- Keywords
- BIOMARKERS, CARDIOVASCULAR BIOMARKERS, DRUG-INDUCED VASCULAR SAFETY, DIAGNOSTIC KITS, BIOMARKER SERVICES, BIOMARKER ASSAY DEVELOPMENT, IN-VITRO DIAGNOSTICS, SAFETY BIOMARKERS, INFLAMMATORY, PROGNOSTIC KITS, BIOMARKERS TESTING, NEXT GENERATION SEQUENCING (NGS), Alzheimer, Immunoassay, Rheumatoid Arthritis, Acute Myocardial Infarction, Olink, HTG Molecular Diagnostics, CRO, Clinical Research Organization, Illumina, Next Generation Sequencing, NGS, qPCR, ELISA, Luminex, MSD, Protein Simple, Flow Cytometry, Assay development, clinical validation, central lab, bioanalysis, bioanalytical service, precision medicine.
- HQ
- HUNINGUE, 68330
Firalis S.a. Questions
Firalis S.A.'s website is firalis.com
Firalis S.A.'s LinkedIn profile is https://fr.linkedin.com/company/firalis
Firalis S.A. has
30 employees.
View email and phone details for 30
employees at Firalis S.A..
Firalis S.A.'s industry is
Biotechnology Research
Firalis S.A.'s top competitors are
Spartha Medical,
Amoneta Diagnostics,
Trench Group,
Proteogenix,
Lodiag,
Biosynex Pharma,
Texcell,
Adipopharma Sas,
Asaria - Assisted Surgery By Augmented Reality & Ia,
Firalis Molecular Precision.
Firalis S.A.'s categories are Biotechnology Research
Firalis S.A.'s founding year is 2008
